FDA 483 - Tris Pharma Inc. - June 08, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Tris Pharma Inc. in Monmouth Junction, NJ, from May to June 2021, revealed significant deficiencies across its quality system, facility maintenance, and manufacturing controls. Observations included inadequate quality unit procedures, failure to properly investigate product complaints and submit field alert reports, and issues with personnel gowning leading to product contamination. The findings highlight a systemic breakdown in ensuring drug product quality and safety.
ID · 098768bd-1d13-4d69-b1b8-fded5b4315eb